This Article Full Text Full Text (PDF) All Versions of this Article: 149/3/1366    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Wang, Z. Articles by Swanson, S. M. PubMed PubMed Citation Articles by Wang, Z. Articles by Swanson, S. M.

Disruption of Growth Hormone Signaling Retards Prostate Carcinogenesis in the Probasin/TAg Rat

Departments of Medicinal Chemistry and Pharmacognosy (Z.W., D.D.L., S.M.S.), Medicine (R.M.L., R.D.K., T.G.U.), Surgical Oncology (K.T.C., S.M.S.), Math, Statistics, and Computer Science (S.H.), Pathology (M.C.B.), and Urology (G.S.P.), University of Illinois at Chicago; Department of Veterans Affairs Jesse Brown Medical Center (T.G.U.); and Provident Hospital of Cook County (V.H.R.), Chicago, Illinois 60612; and Graduate School of Medical Sciences (T.S.), Nagoya City University, 467-8601 Nagoya, Japan

Address all correspondence and requests for reprints to: Steven M. Swanson, Department of Medicinal Chemistry and Pharmacognosy (MC 781), 833 South Wood Street, Chicago, Illinois 60612-7231. E-mail: swanson{at}uic.edu.

We asked whether down-regulation of GH signaling could block carcinogenesis in the Probasin/TAg rat, a model of aggressive prostate cancer. The Spontaneous Dwarf rat, which lacks GH due to a mutation (dr) in its GH gene, was crossed with the Probasin/TAg rat, which develops prostate carcinomas at 100% incidence by 15 wk of age. Progeny were heterozygous for the TAg oncogene and homozygous for either the wild-type GH gene (TAg/Gh^+/+) or the dr mutation (TAg/Gh^dr/dr). Prostate tumor incidence and burden were significantly reduced, and tumor latency was delayed in TAg/Gh^dr/dr rats relative to TAg/Gh^+/+ controls. At 25 wk of age, loss of GH resulted in a 20 and 80% decrease in the area of microinvasive carcinoma in the dorsal and lateral lobes, respectively. By 52 wk of age, invasive prostate adenocarcinomas were observed in all TAg/Gh^+/+ rats, whereas the majority of TAg/Gh^dr/dr did not develop invasive tumors. Suppression of carcinogenesis could not be attributed to alterations in prostate expression of TAg or androgen receptor or changes in serum testosterone levels. As carcinogenesis progressed in TAg/Gh^+/+ rats, prostate GHR mRNA and protein expression increased significantly, but prostate IGF-I receptor mRNA and protein levels dropped. Furthermore, serum IGF-I and prostate IGF-I levels did not change significantly over the course of carcinogenesis. These findings suggest that GH plays a dominant role in progression from latent to malignant prostate cancer driven by the powerful probasin/TAg fusion gene in rats and suggest that GH antagonists may be effective at treating human prostate cancer.